Back to top
more

Alcon (ALC)

(Real Time Quote from BATS)

$89.15 USD

89.15
531,683

-0.13 (-0.15%)

Updated May 15, 2024 10:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (97 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Alcon (ALC) Surgical Arm Grows Amid Global Trade Disruption

by Zacks Equity Research

Segment wise, within Alcon's (ALC) Surgical arm, the portfolio of advanced technology intraocular lenses is driving increased penetration rates of ATIOLs.

Alcon (ALC) Q3 Earnings Beat Estimates, Margin Improves

by Zacks Equity Research

Alcon (ALC) records year-over-year growth across all sales categories in Surgical and Vision Care in Q3.

Abbott's (ABT) Organic Sales Grow Amid Spike in COVID Cases

by Zacks Equity Research

Within Nutrition, the robust year-over-year performance of Abbott's (ABT) U.S. pediatric and international adult nutrition arms drives the company in the third quarter.

STERIS (STE) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Strong performance by the Healthcare, AST and Life Sciences segments is driving the top line for STERIS (STE).

Insulet's (PODD) Omnipod Sales Grow on New Product Upgrade

by Zacks Equity Research

Insulet (PODD) adds significant capacity in preparation for the Omnipod 5 launch in 2021.

Here's Why You Should Retain Bio-Rad (BIO) Stock For Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO) on solid international market performance and raised 2021 guidance.

QIAGEN (QGEN) New Launch to Aid Global TB Elimination Targets

by Zacks Equity Research

QIAGEN's (QGEN) QIAreach QuantiFERON-TB test is now accessible in high burden, low-resource regions.

Abbott's (ABT) Nutrition Arm in Focus on Real Madrid Alliance

by Zacks Equity Research

According to Abbott (ABT), the partnership is set to support education, sports and social welfare activities of at-risk children in 80 countries.

Charles River (CRL) to Offer Cryo-EM Capabilities With New Pact

by Zacks Equity Research

Charles River's (CRL) recent partnership will enable the company to improve drug discovery projects by allowing structure-based design for a greater portfolio of targets.

Here's Why You Should Invest In Henry Schein (HSIC) Now

by Zacks Equity Research

Investors continue to be optimistic about Henry Schein (HSIC) on its extensive global foothold and raised 2021 earnings guidance.

NuVasive (NUVA) Announces Two Developments in Cohere TLIF Line

by Zacks Equity Research

According to NuVasive (NUVA), Porous PEEK is a clear differentiator for the company in the market.

Hologic (HOLX) to Expand Surgical Portfolio With Bolder Buyout

by Zacks Equity Research

Hologic's (HOLX) recent acquisition will accelerate its growth and enhance patient outcomes by leveraging significant commercial resources and strong relationships with OB/GYN specialists.

Quest Diagnostics (DGX) Enhances Lab Experience With Facility

by Zacks Equity Research

Quest Diagnostics (DGX) new facility is fully operational and will empower better health for the patients and clients in the seven states the lab serves.

Quest Diagnostics' (DGX) Efforts to Reduce Health Inequities

by Zacks Equity Research

Quest Diagnostics' (DGX) efforts to support AHA will boost innovative solutions like the Scholars programs, hypertension control and COVID-19 rapid response.

Medtronic (MDT) Sees Business Recovery Despite Volume Pressure

by Zacks Equity Research

According to Medtronic (MDT), healthcare systems are better prepared as vaccination rates continue to increase.

Here's Why You Should Retain Tandem Diabetes (TNDM) for Now

by Zacks Equity Research

Investors are optimistic about Tandem Diabetes (TNDM) owing to robust international pump shipments and product launches.

Here's Why You Should Add STERIS (STE) to Your Portfolio

by Zacks Equity Research

Investors are optimistic about STERIS (STE) owing to elevated consumer demand and rebound in procedure volumes and raised 2022 outlook.

Here's Why You Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) owing to new product launches in the SDB market and strong sales of mask products.

Hill-Rom (HRC) New LT Strategy Aids, Y/Y Comparisons Ail

by Zacks Equity Research

Hill-Rom's (HRC) newly initiated long-term growth strategies through fiscal 2022, focusing on all four strategic priorities, look attractive at this moment.

Here's Why You Should Retain Haemonetics (HAE) Stock for Now

by Zacks Equity Research

Investors are optimistic about Haemonetics (HAE) on strong demand for NexSys PCS system and potential of Hemostasis Management franchise.

Henry Schein (HSIC) Dental Sales Grow Globally Despite Pandemic

by Zacks Equity Research

Widespread network and channel mix along with favorable long-term trends in the dental business bode well for Henry Schein (HSIC).

Haemonetics (HAE) Rides on Plasma Arm Recovery Amid COVID Woes

by Zacks Equity Research

Haemonetics' (HAE) hospital business is recovering primarily driven by continued improvement in hospital procedures.

QIAGEN (QGEN) to Boost NeuMoDx Production With US DOD Contract

by Zacks Equity Research

QIAGEN's (QGEN) NeuMoDx platforms offer a unique combination of speed, flexibility, throughput and ease of use for molecular diagnostics testing, including laboratory-developed tests.

Here's Why You Should Hold on to Thermo Fisher (TMO) for Now

by Zacks Equity Research

Investors are optimistic about Thermo Fisher (TMO) on strength in end markets and raised 2021 guidance.

Alcon's (ALC) Robust Product Line, Market Rebound Aid Growth

by Zacks Equity Research

In Presbyopia-correcting Intraocular Lens (PCIOLs), Alcon (ALC) currently leads the market with over 55% of global share and over 80% share in the United States.